CN102058568B - Application of germacrone - Google Patents
Application of germacrone Download PDFInfo
- Publication number
- CN102058568B CN102058568B CN201010604066A CN201010604066A CN102058568B CN 102058568 B CN102058568 B CN 102058568B CN 201010604066 A CN201010604066 A CN 201010604066A CN 201010604066 A CN201010604066 A CN 201010604066A CN 102058568 B CN102058568 B CN 102058568B
- Authority
- CN
- China
- Prior art keywords
- hpv
- dimethyl
- cyclodecadien
- methylethylidene
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses new application of germacrone, in particular to application of germacrone in preparing a medicament for treating HPV (Human Papilloma Virus) infection, belonging to the technical field of medicines. The invention confirms that germacrone has good preventing and treating effect on cervical carcinoma caused by HPV infection in a plurality of factors causing cervical carcinoma through test research.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of new purposes of middle pharmaceutically active ingredient.
HPV according to the invention is meant the human papillomavirus.
Background technology
Middle pharmaceutically active ingredient is material base of its performance drug action, and the comprehensive quality control of clear and system of active substance is the key and the core of the modernization of Chinese medicine, and the curative effect material pesticide effect research of Chinese medicine is clear; Thereby replace effective ingredient in Chinese or extract, could ensure its quality homogeneous, stable curative effect, controlled safely, become standard active ingredient; Be prepared into medicine as crude drug; Therefore, carry out deep research in the centering pharmaceutically active ingredient, have profound significance; Help the modernization of Chinese medicine, help Chinese medicine to go to the world, help the healthy of the mankind more.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is one of effective ingredient in the Chinese medicine Rhizoma Curcumae, and the open 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-of Chinese patent (application number is 02125900.3) is used for antitumor cell, does not retrieve the document that 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is used for treating cervical cancer separately.
The paathogenic factor of cervical cancer is not studied clear now, studies more its pathogenesis of thinking at present and comprises that mainly (virus causes the cervical cancer Research Progress in Pathogenesis for human papillomavirus, herpesvirus, HIV; Yang Lili, Tong Xiuqin; 2009 the 41st the 8th phases of volume of Inner Mongol medical journal Inner Mongolia Med J), (correlation analysiss of reproductive tract infection and precancerous lesions of uterine cervix and cervical cancer such as chlamydia, bacterial infection, infusorian; Yang Jie; The practical medicine of China the 5th the 27th phase of volume of JIUYUE in 2010), therefore, cause in the cervical cancer factor numerous; It is most important that the proof 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-causes cervical cancer to have a therapeutical effect to what reason; And this deep research can well be proved conclusively 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-and can be treated this disease of cervical cancer, is the announcement of 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-control effect and mechanism; For 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-in the new drug development process, definite, deep theoretical basis is provided.
Summary of the invention
For these reasons; The scientific research personnel of our company passes through experimentation; From the paathogenic factor of numerous cervical cancers, study and proved that 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-infects HPV and has good therapeutical effect, explain that the 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-cervical cancer that infection causes to HPV has excellent prevention and therapeutical effect; Particularly content is more than or equal to 50% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-, with commercially available Oleum Curcumae relatively, have better pharmacological action; Compare less than 50% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-with content, also have better pharmacological action.
The present invention realizes through following technical proposals.
The application of 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-in preparation treatment HPV infection medicine.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-infects the application in the cervical disease medicine that causes at preparation treatment HPV.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-infects the application in the cervical cancer medicine that causes at preparation treatment HPV.
Wherein 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content more than or equal to 50% less than 100%.
Wherein HPV is high-risk human mammilla papillomavirus hypotype or low risk human papillomavirus hypotype.
Wherein the HPV type is one or more in 16,18,26,31,33,35,39,45,51,52,53,56,58,66,59,68,73 and 82 types.
Wherein the HPV type be 6,11,40,42,43,44,54,61,70,72,81,83 and 89 types one or more.
Wherein the 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-site of action includes but not limited to E6 and E7 albumen among the HPV.
Wherein 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the pharmaceutical preparation of active component.
Wherein pharmaceutical preparation is oral formulations, ejection preparation, vagina preparation or rectal formulation.
Wherein oral formulations is tablet, granule, capsule, drop pill or oral liquid; Wherein ejection preparation is injectable emulsion or lyophilized injectable powder; Wherein vagina preparation is suppository, soft capsule, effervescent tablet, gel, ointment, vaginal tablet, membrane or foam; Wherein rectal formulation is suppository or soft capsule.
HPV according to the invention is meant the human papillomavirus.
Pharmacology test
Test the effect of 1 anti-human papilloma virus (anti-HPV)
Test reagent: HPV nucleic acid amplification (PCR) fluorescence detection reagent kit (comprising DNA extraction liquid 1, DNA extraction liquid 2, PCR reactant liquor, Taq enzyme, UNG).Other reagent are analytical pure.
Trial drug:
Test 1 group: commercially available Oleum Curcumae.
Test 2 groups: content is 47.4% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-.
Test 3 groups: content is 92.8% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-.
Test method:
Sample preparation: above-mentioned test 1 assembly is set to 500 μ g/ml solution; Test 2 assembly and be set to 20 μ g/ml solution; To test 3 and be configured to 300 μ g/ml solution; Test 3 assembly and be set to 150 μ g/ml; Test 3 assembly and be set to 50 μ g/ml; Test 3 assembly and be set to 20 μ g/ml; Test 3 assembly and be set to 10 μ g/ml;
The preparation of HPV infected specimen: be diagnosed as HPV from hospital outpatient and infect the isolated preparation of taking (the HPV type is 16,52,58 mixed types), focus in 1 centrifuge tube, 30mg weighs; Use glass homogenizer homogenate; Add the 5mL normal saline again, be made into the stripped suspension of 6mg/mL, subsequent use.
The method of sample treatment: draw 25 μ L sample liquid and 25 μ L BIAO and BEN suspensions to the 15mL centrifuge tube with liquid-transfering gun; Jolting is even, and sample and BIAO and BEN can fully be acted on, and puts 37 ℃ of water baths and cultivates; Behind sample treatment BIAO and BEN 1d, 3d, 5d, 7d, respectively get 1 group and carry out following test.
The extraction of HPV-DNA: from warm bath cabinet, take out BIAO and BEN suspension, extract DNA by the test kit step: add 50 μ L normal saline, add 100 μ LDNA extracting solution behind the mixing again through sample treatment; Jolting is even, the centrifugal 10min of 1200r/min, abandoning supernatant; Add 25 μ L DNA extraction liquid 2 again, abundant mixing, 100 ℃ of boiling water boil 10min; The centrifugal 10min of 1200r/min, supernatant is the HPV-DNA template.
DNA cloning: get the PCR reactant liquor 37.6 μ L in the detection kit, Taq archaeal dna polymerase 0.4 μ L, UNG0.03 μ L add HPV-DNA template 2 μ L again in the PCR reaction tube, and button strict control lid places quantitative PCR appearance cocycle amplification.HPV-DNA carries out cyclic amplification through high-temperature denatured, process annealing and extension, and cyclic program is set to: 37 ℃, and 5min; 94 ℃, 1min; 95 ℃, 5sec; 60 ℃, 30sec circulates 40 times.
Amount standard curve: detect quantitatively with fluorescent probe,, set up the quantitative positive criteria article of HPV-DNA of 4 series concentration, be followed successively by 5 * 10 according to the detection kit requirement
7/ mL, 5 * 10
6/ mL, 5 * 10
5/ mL, 5 * 10
4/ mL, (its detection sensitivity is 1 * 10 through the PCR detection
3/ mL, the result is judged to be feminine gender less than this concentration person).Natural logrithm with initial copy number is an abscissa, and cycle threshold is a vertical coordinate, and the regression straight line that obtains is a standard curve, in view of the above the amplification times of sample is carried out quantitatively.
Result of the test: see table 1.
The DNA exercising result that table 1 different tests medicine infects HPV
Annotate :-represent negative.
The HPV infected specimen changed into be diagnosed as HPV from hospital outpatient and infect the isolated preparation (16,18,31,33,35,39,58,59,68,73 and 82 type) take; Make an experiment according to the method described above, test 1 day, 3 days, 5 days, 7 days result of 3 groups of (20-300 μ g/ml) (content is 89.7% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-) cultivations and be all feminine gender; 5 days results are negative to test 2 groups of (content is 49.9% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-) incubation times, and incubation time 7 days is feminine gender as a result; It is negative to test 7 days results of 1 group of cultivation.
The HPV infected specimen changed into be diagnosed as HPV from hospital outpatient and infect the isolated preparation (the HPV type is 26,53 and 66 types) take; Make an experiment according to the method described above, test 1 day, 3 days, 5 days, 7 days result of 3 groups of (20-300 μ g/ml) (content is 73.3% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-) cultivations and be all feminine gender; 5 days results are negative to test 2 groups of (content is 25.6% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-) incubation times, and incubation time 7 days is feminine gender as a result; It is negative to test 7 days results of 1 group of cultivation.
The HPV infected specimen changed into be diagnosed as HPV from hospital outpatient and infect the isolated preparation (the HPV type is 6,11,40,44,54,72,81,83 and 89 types) take; Make an experiment according to the method described above, test 1 day, 3 days, 5 days, 7 days result of 3 groups of (20-300 μ g/ml) (content is 50.1% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-) cultivations and be all feminine gender; 5 days results are negative to test 2 groups of (content is 18.9% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-) incubation times, and incubation time 7 days is feminine gender as a result; It is negative to test 7 days results of 1 group of cultivation.
Conclusion (of pressure testing): above-mentioned test data shows that the DNA that in 3 groups of the tests HPV is infected has the good restraining effect.
Test 2
Influence to the effect of HPVE6E7 gene inhibition
Test material:
Cervical cancer tumer line: human cervical carcinoma CaSKi cell line (HPV16 is positive, HPV53 is positive, HPV83 is positive); People's cervix uteri squamous epithelial cancer immortalized cell line H8 (HPV-56 is positive, HPV66 is positive, HPV42 is positive).
Primer: by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd, it is synthetic to use U.S. PE company 391 type automatic dna synthesizers, purification mode: PAGE.
Culture medium and serum: Dulbecco ' s Modified Eagle Medium (DMEM) culture medium (GIBCO BRL), hyclone (river, Tianjin page or leaf biochemical product company limited); Toolenzyme: Taq archaeal dna polymerase (Promega), reverse transcriptase (AMV Reverse Transcriptase) (Promega).
Trial drug:
Test 1 group: commercially available Oleum Curcumae.
Test 2 groups: content is 44.6% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-.
Test 3 groups: content is 93.4% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-.
Experimental technique
The cultivation of cervical cancer tumer line: human cervical carcinoma CaSKi cell is in the DMEM of 5% hyclone culture medium, and the H8 cell is in containing the DMEM culture medium of 2% hyclone, and 37 ℃, 5%CO2 saturated humidity environment is cultivated down.
Drug level is selected: different experiments group drug level 150 μ g/ml.
Cellular morphology is observed: living cells is taken a picture: with the cell inoculation of exponential phase in 6 orifice plate culture plates, every hole 10 * 10
4Individual cell, a slice coverslip is placed in every hole in 6 well culture plates of each experimental group, forms the cover plate with cell, is replaced by the pastille culture medium behind second day cell attachment, cultivates after three days observation of cell form and photograph under inverted microscope.
The blue colorimetry of tetramethyl azo azoles detects different pharmaceutical to CaSKi cell and H8 cell growth inhibited situation: in 96 porocyte culture plates, 3000 cells in every hole added different medicinal liquids in second day with cell inoculation; Parallel 5 holes of each concentration, 37 ℃, 5%CO2 cultivates blue (MTT) 20 μ l of every hole adding 5mg/ml tetramethyl azo azoles after 24 hours; Continue to cultivate 4 hours; Abandoning supernatant, every hole adds dimethyl sulfoxide 150 μ l, cultivates ELIASA 492nm mensuration OD value after 20 minutes.
Cell cycle detects: the same method in six well culture plates with the culture medium culturing that contains the variable concentrations medicine five days, parallel 3 holes of each drug level, collecting cell, the preparation single cell suspension, PBS cleans 2 times, pre-cooling 70% ethanol is fixed, 4 ℃ of preservations are to be checked.Handle endochylema RNA, 50mg/L iodate third ingot (popidium iodide through the 0.01%RNA enzyme; PI) behind the DNA dyeing 30min; Remove by filter agglomerating cell through 300 mesh sieves, use COULTER EPICS XL flow cytometer and detect in the cell cycle not the natural death of cerebral cells rate of phase simultaneously.Every part of BIAO and BEN is measured 5000 cells, phase when distinguishing cell cell cycle of living in according to dna content.
The mDNA detection of expression: collect to cultivate the 5th day cell, TRIZOL handles the back and extracts RNA, and reverse transcription is cDNA, and amplification HPV E6, E7, the β-action that increases simultaneously be as internal reference, HPV E6, E7 primer (616bp):
Upper reaches 5`-TGACTTTGCTTTTCGGGGATT-3`,
Downstream 5`-GAGAACAGATGGGGCACAC-3`.
β-action (552bp) primer sequence: the upper reaches: 5`-ATCATGTTTGAGACCTTCAACACC-3`, downstream 5`-CATGGTGGTGCCGCCGCCAGACAG-3`.
The amplification parameter is: 94 ℃ of preparatory degeneration 5min; 94 ℃ of degeneration 45s, 50 ℃ of renaturation 45s, 72 ℃ are extended 1min, 30 circulations of increasing; 72 ℃ are extended added-time 5min; 4 ℃ of preservations of PCR product; 2% agarose gel electrophoresis observed result, voltage 40V.Use the semi-quantitative analysis that Scion Image 4.0 (NIH) software carries out electrophoretic band image ash value.Testing gene electrophoretic band gray level ratio=band gray value to be measured/with a BIAO and BEN internal reference β-action band gray value.
Use SPSS 13.0.0 statistical software, carry out one factor analysis of variance (ANOVA), t check etc.
The growth inhibited effect of table 2 pair CaSki cell (OD, n=5) absorbance (OD)
Annotate: compare #P＜0.05, ##P＜0.01 with the control group; Compare for 1 group with test
*P＜0.05; Compare Δ P＜0.05 for 2 groups with test.
The growth inhibited effect of table 3 pair H8 cell (OD, n=5) absorbance (OD)
Annotate: compare #P＜0.05, ##P＜0.01 with the control group; Compare for 1 group with test
*P＜0.05; Compare Δ P＜0.05 for 2 groups with test.
The influence of table 4 couple HPVE6, E7 gene expression (CaSKi cell cycle distribution and apoptosis rate)
Annotate: compare #P＜0.05, ##P＜0.01 with the control group.
The influence of table 5 couple HPVE6, E7 gene expression (H8 cell cycle distribution and apoptosis rate)
Annotate: compare #P＜0.05, ##P＜0.01 with the control group.
Table 6RT-PCR product electrophoretic band gray value
Annotate: compare #P＜0.05, ##P＜0.01 with the control group.
Conclusion (of pressure testing): above-mentioned test 1 has proved 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-with test 2, and infection has fine inhibitory action to HPV, the HPV different subtype is infected have the good restraining effect, mainly acts on its E6, E7 albumen; Relatively has better pharmacological action with Oleum Curcumae; Be lower than 50% 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-with content and relatively have better pharmacological action.
Preparation embodiment
Embodiment 1
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the tablet of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 42.3%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 2
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the capsule of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 59.4%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 3
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the injectable emulsion of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 76.7%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 4
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the lyophilized injectable powder of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 84.6%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 5
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the vaginal suppository of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 68.2%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 6
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the vaginal foam agent of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 52.6%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 7
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the vagina effervescence of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 71.6%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 8
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the rectal suppository of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 95.0%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 9
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the vagina gel of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 90.1%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 10
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the vagina ointment of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 56.3%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 11
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the vagina membrane of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 41.0%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
Embodiment 12
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-is the rectum soft capsule of active component preparation, and said preparation is used to treat HPV and infects the disease that causes, and includes but not limited to cervical disease or cervical cancer.
3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content is 33.6%; The HPV infection type includes but not limited to high-risk-type human nipple virus hypotype or low risk human papillomavirus hypotype through detection.
The foregoing description includes but not limited to said.
Claims (5)
1. the application of 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-in preparation treatment human papilloma virus infection medicine; Wherein 3,7-Cyclodecadien-1-one, 3,7-dimethyl-10-(1-methylethylidene)-, (E,E)-content be 92.8% or content be 93.4%.
2. application according to claim 1, wherein the human papillomavirus is high-risk human mammilla papillomavirus hypotype or low risk human papillomavirus hypotype.
3. application according to claim 1, wherein human papillomavirus's type is one or more in 16,18,26,31,33,35,39,45,51,52,53,56,58,66,59,68,73 and 82 types.
4. application according to claim 1, wherein human papillomavirus's type be 6,11,40,42,43,44,54,61,70,72,81,83 and 89 types one or more.
5. according to each described application of claim 3-4, wherein the human papillomavirus comprises E6 and E7 albumen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010604066A CN102058568B (en) | 2010-12-24 | 2010-12-24 | Application of germacrone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010604066A CN102058568B (en) | 2010-12-24 | 2010-12-24 | Application of germacrone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058568A CN102058568A (en) | 2011-05-18 |
| CN102058568B true CN102058568B (en) | 2012-10-17 |
Family
ID=43994197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010604066A Active CN102058568B (en) | 2010-12-24 | 2010-12-24 | Application of germacrone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058568B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505444A (en) * | 2012-06-19 | 2014-01-15 | 华中科技大学 | Application of germacrone in preparation of liver cancer treatment medicines |
| CN108714117B (en) * | 2018-07-06 | 2021-04-27 | 浙江丽芙秀化妆品有限公司 | Long-acting perfume and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1471908A (en) * | 2002-08-01 | 2004-02-04 | 大连医大安鹏生物医药技术有限公司 | Sesquiterpene ketone injection, preparing method and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01121234A (en) * | 1987-11-02 | 1989-05-12 | Showa Denko Kk | Production of 4-hydroxybutanals |
| JPH01139527A (en) * | 1987-11-25 | 1989-06-01 | Eisai Co Ltd | Central inhibitant |
-
2010
- 2010-12-24 CN CN201010604066A patent/CN102058568B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1471908A (en) * | 2002-08-01 | 2004-02-04 | 大连医大安鹏生物医药技术有限公司 | Sesquiterpene ketone injection, preparing method and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058568A (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lobo et al. | Vitreous aspiration needle tap in the diagnosis of intraocular inflammation | |
| Rosa et al. | The prevalence of human papillomavirus in ovarian cancer: a systematic review | |
| CN103920081B (en) | Purpose of pharmaceutical composition | |
| Natphopsuk et al. | Human papillomavirus genotypes and cervical cancer in northeast Thailand | |
| Nadji et al. | Relationship between lung cancer and human papillomavirus in north of Iran, Mazandaran province | |
| Brown et al. | Human papillomavirus infections of the genital tract | |
| CN109554506A (en) | It is a kind of for detecting the design method of the primer and probe of pathogen | |
| Doosti et al. | Lack of evidence for a relationship between high risk human papillomaviruses and breast cancer in Iranian patients | |
| CN104017907B (en) | A kind of HPV high-risk-type fluorescence PCR detection reagent kit | |
| CN101791392B (en) | Medicinal composition for treating human papillomavirus persistent infection | |
| CN102058568B (en) | Application of germacrone | |
| CN104523821A (en) | Application of shrubby sophora extract in treatment of HPV | |
| CN104257745B (en) | A kind of Polysaccharides from Prunella vulgaris L extract and preparation method thereof, preparation and purposes | |
| CN102091064B (en) | Use of furanodiene | |
| CN102716115A (en) | Pharmaceutical composition | |
| CN102091065A (en) | Application of curcumenol | |
| CN102091059A (en) | Application of curdione | |
| CN105362736A (en) | Medicine for treating chicken coccidiosis and preparation method of medicine | |
| CN104846116A (en) | PCR primer groups and probe used for detecting human immunodeficiency virus type I, kit containing PCR primer groups and probe, and detection method | |
| CN101199498A (en) | Medicament of anti-nipple tumor virus infection | |
| CN102178668A (en) | Application of linoleic acid in preparing human papillomavirus (HPV) resisting medicament | |
| Jiang et al. | HPV infection downregulates the expression of autophagy-related genes in condylomata acuminata | |
| CN105381024A (en) | Pharmaceutical composition for treating chicken coccidiosis and preparation method thereof | |
| CN104324073B (en) | Application of the shrubby sophora extract in HPV is treated | |
| CN110292621A (en) | The antitoxin antibacterial complexing agent of anti-HPV viruse infection and its preparation method of phase inversion gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |